$98.3 Million is the total value of Alerce Investment Management, L.P.'s 7 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q4 2021 | ||||||||
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-09
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMERICAN WELL CORP | 15 | Q2 2024 | 62.9% |
| ANNEXON INC | 15 | Q2 2024 | 71.1% |
| AKEBIA THERAPEUTICS INC | 15 | Q2 2024 | 31.6% |
| AADI BIOSCIENCES INC | 12 | Q2 2024 | 24.1% |
| ASSEMBLY BIOSCIENCES INC | 12 | Q3 2023 | 8.7% |
| AILERON THERAPEUTICS INC | 8 | Q3 2022 | 14.4% |
| GLOBAL BLOOD THERAPEUTICS IN | 8 | Q3 2022 | 23.4% |
| AILERON THERAPEUTICS INC | 6 | Q1 2024 | 5.8% |
| AERPIO PHARMACEUTICALS INC | 3 | Q2 2021 | 5.2% |
| VERONA PHARMA PLC | 1 | Q2 2024 | 6.0% |
View Alerce Investment Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-09 |
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-04 |
| 13F-HR | 2022-05-13 |
View Alerce Investment Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.